A Phase 3 interventional study of Placebo Matching Mitapivat and Mitapivat in Non-Transfusion-dependent Alpha-Thalassemia and Non-Transfusion-dependent Beta-Thalassemia, sponsored by Agios Pharmaceuticals, Inc.. Active, not recruiting at 68 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Agios Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in beta-Thalassemia with a site in Italy — 8 open to participants now, 17 under way, 6 of them phase 3. beta-Thalassemia · Italy.
Among the 49 studies in beta-Thalassemia with a site in Italy, this one is the 7th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2021, is one of 11 in phase 3, reaches primary completion later than 0 of the 16 other live ones, and was the 38th registered.
294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.
Browse beta-Thalassemia studies →8 of the 49 studies in beta-Thalassemia with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Telethon · Sites in Italy
Ages 3–35
Cyprus Institute of Neurology and Genetics · Sites in Italy, United States, Angola and 13 more countries
Ages 2+
Vertex Pharmaceuticals Incorporated · Sites in Italy, United States, Germany and 1 more country
Ages 12–35
Celgene · Sites in Italy, United States, China and 6 more countries
Ages 6–17
Celgene · Sites in Italy, United States, Australia and 19 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 21 · Phase 3 13 · Phase 4 4
First in 2000; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 194 is above the median of 40 across 208 interventional studies indexed under beta-Thalassemia.
Median enrollment 55 across the 39 interventional studies, 120 across the 10 observational. Of the 29 that completed or were terminated, 15 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 49 have an industry lead sponsor. The 10 most frequent:
Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.
Agios Pharmaceuticals, Inc. has 4 studies filed under beta-Thalassemia — fewer than ten, so there is no comparison to draw.
5 of the studies in beta-Thalassemia with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
| NCT05356195Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | 2027-11-14 |
| NCT06421636Regeneron PharmaceuticalsA Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body | 2026-12-03 |
| NCT01639690San Rocco Therapeuticsß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene | 2027-07 |
| NCT05799118Cyprus Institute of Neurology and GeneticsStudy of the Role of Genetic Modifiers in Hemoglobinopathies | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 49 studies in beta-Thalassemia with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study was to compare the effect of mitapivat versus placebo on hemolytic anemia in participants with alpha- or beta-non-transfusion dependent thalassemia (NTDT).
The mitapivat group included 130 participants whereas the placebo group had 64 participants.
294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.
This study's enrollment of 194 is above the median of 40 across 208 interventional studies indexed under beta-Thalassemia.
Browse beta-Thalassemia studies →Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.
Compared within beta-Thalassemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Thalassemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any medical, hematological, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study and/or could confound the interpretation of the study data Also excluded are:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mitapivat 100 milligrams (mg), orally, twice daily (BID) for 24 weeks in double blind (DB) period and for up to 5 years in open label extension (OLE) period.
Drug: Mitapivat
Placebo matching mitapivat, orally, BID for 24 weeks in double blind period followed by Mitapivat 100 mg, orally, BID for up to 5 years in open label extension period.
Drug: Placebo Matching Mitapivat · Drug: Mitapivat
Tablets
Tablets
Also known as: AG-348, AG-348 sulfate hydrate, Mitapivat sulfate
Double-Blind Period: Percentage of Participants Who Achieved Hemoglobin (Hb) Response From Week 12 Through Week 24 Compared With Baseline
Hb response is defined as ≥10 grams/ liter (g/L) (1.0 gram per deciliter) (g/dL) increase in average Hb concentration from Week 12 through Week 24 compared with baseline. Hb response was tested using the Mantel-Haenszel stratum weighted method adjusting for randomization stratification factors. Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
Time frame: Double-Blind Period: Baseline up to Week 12 through Week 24
Double-Blind Period: Change From Baseline in Average Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue Subscale Score From Week 12 Through Week 24
The FACIT-Fatigue subscale includes a 13-item self-reported fatigue subscale, which assesses the severity and impact of fatigue (including the impact on daily activities and functioning).The FACIT-Fatigue subscale is scored on a 5-point Likert scale: 0 (not at all) to 4 (very much). The total FACIT-Fatigue subscale score ranges from 0 to 52, with a higher score indicating better health-related quality of life (HRQOL). Baseline is defined as the last assessment before randomization for subjects randomized and not dosed or the last assessment before start of study treatment for subjects randomized and dosed.
Time frame: Double-Blind Period: Baseline, Week 12 through Week 24
Double-Blind Period: Change From Baseline in Average Hb Concentration From Week 12 Through Week 24
Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
Time frame: Double-Blind Period: Baseline, Week 12 through Week 24
Double-Blind Period: Percentage of Participants Who Achieved Hb 1.5+ Response From Week 12 Through Week 24 Compared With Baseline
Hb 1.5+ response is defined as a ≥1.5 g/dL increase in average Hb concentration from Week 12 through Week 24 compared with baseline. Hb 1.5+ response will be summarized using the Mantel-Haenszel stratum weighted method adjusting for randomization stratification factors. Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
Time frame: Double-Blind Period: Baseline up to Week 12 through Week 24
Double-Blind Period: Change From Baseline in Indirect Bilirubin at Week 24
Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
Time frame: Double-Blind Period: Baseline, Week 24
Double-Blind Period: Change From Baseline in Lactate Dehydrogenase (LDH) at Week 24
Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
Time frame: Double-Blind Period: Baseline, Week 24
Double-Blind Period: Change From Baseline in Haptoglobin at Week 24
Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
Time frame: Double-Blind Period: Baseline, Week 24
Double-Blind Period: Change From Baseline in Reticulocytes at Week 24
Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
Time frame: Double-Blind Period: Baseline, Week 24
Double-Blind Period: Change From Baseline in Erythropoietin at Week 24
Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
Time frame: Double-Blind Period: Baseline, Week 24
Double-Blind Period: Percentage of Participants Who Achieved Patient Global Impression of Severity (PGIS)- Fatigue Response at Weeks 12, 16, 20, and 24
PGIS-Fatigue measured participants' perception of their fatigue severity (7-day recall) on a 4-point scale ranging from '1=none' to '4=severe'. A participant was considered to have achieved the PGIS-Fatigue response at Weeks 12, 16, 20, or 24, if their baseline to postbaseline score met one of the following conditions: 'none' at baseline to 'none' postbaseline; 'mild' to 'mild' or 'none'; 'moderate' to 'mild' or 'none'; or 'severe' to 'moderate', 'mild', or 'none'.
Time frame: Double-Blind Period: At Weeks 12, 16, 20, and 24
Double-Blind Period: Percentage of Participants Who Achieved the Patient Global Impression of Change (PGIC)- Fatigue Response at Weeks 12, 16, 20, and 24
The PGIC-Fatigue assesses change over time compared with baseline on a 5-point scale ranging from 0 to 4 where 0 indicates Much better and 4 as Much worse. A participant was considered to have achieved the PGIC-Fatigue response at Weeks 12, 16, 20, or 24 if their baseline PGIS and corresponding PGIC met one of the following conditions: if the PGIS at baseline was 'none' or 'mild' and PGIC at the visit was 'no change', 'a little better', or 'much better'; or if the PGIS at baseline was 'moderate' or 'severe' and PGIC at the visit was 'a little better' or 'much better'.
Time frame: Double-Blind Period: At Weeks 12, 16, 20, and 24
Double-Blind Period: Change From Baseline in the 6-minute Walk Test (6MWT) Distance at Week 24
The 6MWT is a well-established performance outcome (PerfO) measure that is widely used to evaluate physical activity in terms of distance walked in patients with a variety of conditions. The test measures the distance an individual can walk on a hard, flat surface in 6 minutes.
Time frame: Double-Blind Period: Baseline, Week 24
Double-Blind Period: Change From Baseline in Serum Ferritin at Week 24
Iron metabolism was assessed based on serum ferritin levels.
Time frame: Double-Blind Period: Baseline, Week 24
Double-Blind Period: Change From Baseline in Transferrin Saturation (TSAT) at Week 24
Iron metabolism was assessed based on TSAT levels. Transferrin saturation is reported by dividing value of serum iron by total iron binding capacity.
Time frame: Double-Blind Period: Baseline, Week 24
Double-Blind Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity Greater Than or Equal to Grade 3
AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of AEs was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.
Time frame: Double-Blind Period: From the time of signing informed consent to Week 24
Double-Blind Period: Plasma Concentration of Mitapivat
Time frame: Double-Blind Period: Pre-dose at Week 12; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Double-Blind Period: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mitapivat
Area under the concentration-time curve from time zero to Tlast on dosing day, calculated using the linear-log trapezoidal rule.
Time frame: Double-Blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Double-Blind Period: Time of Last Quantifiable Concentration (Tlast) of Mitapivat
Time frame: Double-Blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Double-Blind Period: Maximum Observed Plasma Concentration (Cmax) of Mitapivat
Time frame: Double-Blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Double-Blind Period: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mitapivat
Time frame: Double-Blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Double-Blind Period: Last Quantifiable Plasma Concentration (Clast) of Mitapivat
Time frame: Double-Blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Double-Blind Period: Blood Concentration of Adenosine Triphosphate (ATP)
Time frame: Double-Blind Period: Pre-dose at Day 1; pre-dose at Week 12; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Double-Blind Period: Blood Concentration of 2,3 - Diphosphoglycerate (2,3-DPG)
Time frame: Double-Blind Period: Pre-dose at Day 1; pre-dose at Week 12; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Open-Label Extension Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity of Greater Than or Equal to Grade 3
AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of abnormalities was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.
Time frame: Open-Label Extension Period: From week 24 up to end of study (approximately 5 years)
Participants took part in study at study sites in the United States of America, Brazil, Bulgaria, Canada, Denmark, France, Greece, Italy, Lebanon, Malaysia, Netherlands, Saudi Arabia, Spain, Taiwan, Thailand, Turkey, United Arab Emirates and the United Kingdom. Results are reported for 24-week DB period until primary completion date. Analysis of data for OLE period is still ongoing with anticipated completion in December 2028. Results for OLE period will be reported by December 2029.
| Milestone | Mitapivat | Placebo |
|---|---|---|
| Started | 130 | 64 |
| Treated | 129 | 63 |
| Completed | 122 | 62 |
| Not completed | 8 | 2 |
| Withdrew: Randomized, never treated | 1 | 1 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Other un-specified | 1 | 0 |
Hb response is defined as ≥10 grams/ liter (g/L) (1.0 gram per deciliter) (g/dL) increase in average Hb concentration from Week 12 through Week 24 compared with baseline. Hb response was tested using the Mantel-Haenszel stratum weighted method adjusting for randomization stratification factors. Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
| Percentage of participants | Mitapivat | Placebo |
|---|---|---|
| Double-Blind Period: Percentage of Participants Who Achieved Hemoglobin (Hb) Response From Week 12 Through Week 24 Compared With Baseline | 42.3 | 1.6 |
The FACIT-Fatigue subscale includes a 13-item self-reported fatigue subscale, which assesses the severity and impact of fatigue (including the impact on daily activities and functioning).The FACIT-Fatigue subscale is scored on a 5-point Likert scale: 0 (not at all) to 4 (very much). The total FACIT-Fatigue subscale score ranges from 0 to 52, with a higher score indicating better health-related quality of life (HRQOL). Baseline is defined as the last assessment before randomization for subjects randomized and not dosed or the last assessment before start of study treatment for subjects randomized and dosed.
| score on a scale | Mitapivat | Placebo |
|---|---|---|
| Double-Blind Period: Change From Baseline in Average Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue Subscale Score From Week 12 Through Week 24 | 4.85 ± 0.732 | 1.46 ± 0.955 |
Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
| Gram per Liter (g/L) | Mitapivat | Placebo |
|---|---|---|
| Double-Blind Period: Change From Baseline in Average Hb Concentration From Week 12 Through Week 24 | 8.57 ± 0.666 | -1.06 ± 0.867 |
Hb 1.5+ response is defined as a ≥1.5 g/dL increase in average Hb concentration from Week 12 through Week 24 compared with baseline. Hb 1.5+ response will be summarized using the Mantel-Haenszel stratum weighted method adjusting for randomization stratification factors. Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
| Percentage of participants | Mitapivat | Placebo |
|---|---|---|
| Double-Blind Period: Percentage of Participants Who Achieved Hb 1.5+ Response From Week 12 Through Week 24 Compared With Baseline | 24.6 | 0 |
Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
| Micromole per Liter (umol/L) | Mitapivat | Placebo |
|---|---|---|
| Double-Blind Period: Change From Baseline in Indirect Bilirubin at Week 24 | -10.65 ± 1.047 | -0.03 ± 1.403 |
Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
| Units per Liter (U/L) | Mitapivat | Placebo |
|---|---|---|
| Double-Blind Period: Change From Baseline in Lactate Dehydrogenase (LDH) at Week 24 | -30.07 ± 7.131 | -5.79 ± 9.440 |
Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
| Gram per Liter (g/L) | Mitapivat | Placebo |
|---|---|---|
| Double-Blind Period: Change From Baseline in Haptoglobin at Week 24 | -0.002 ± 0.0145 | 0.017 ± 0.0199 |
Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
| 10^9 cells per liter (10^9 cells/L) | Mitapivat | Placebo |
|---|---|---|
| Double-Blind Period: Change From Baseline in Reticulocytes at Week 24 | -32.11 ± 10.600 | -14.74 ± 14.932 |
Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.
| International units per Liter (IU/L) | Mitapivat | Placebo |
|---|---|---|
| Double-Blind Period: Change From Baseline in Erythropoietin at Week 24 | 19.21 ± 37.773 | 115.71 ± 49.413 |
PGIS-Fatigue measured participants' perception of their fatigue severity (7-day recall) on a 4-point scale ranging from '1=none' to '4=severe'. A participant was considered to have achieved the PGIS-Fatigue response at Weeks 12, 16, 20, or 24, if their baseline to postbaseline score met one of the following conditions: 'none' at baseline to 'none' postbaseline; 'mild' to 'mild' or 'none'; 'moderate' to 'mild' or 'none'; or 'severe' to 'moderate', 'mild', or 'none'.
| percentage of participants | Mitapivat | Placebo |
|---|---|---|
| At Week 12 | 65.4 | 46.9 |
| At Week 16 | 63.1 | 42.2 |
| At Week 20 | 61.5 | 48.4 |
| At Week 24 | 62.3 | 46.9 |
The PGIC-Fatigue assesses change over time compared with baseline on a 5-point scale ranging from 0 to 4 where 0 indicates Much better and 4 as Much worse. A participant was considered to have achieved the PGIC-Fatigue response at Weeks 12, 16, 20, or 24 if their baseline PGIS and corresponding PGIC met one of the following conditions: if the PGIS at baseline was 'none' or 'mild' and PGIC at the visit was 'no change', 'a little better', or 'much better'; or if the PGIS at baseline was 'moderate' or 'severe' and PGIC at the visit was 'a little better' or 'much better'.
| percentage of participants | Mitapivat | Placebo |
|---|---|---|
| At Week 12 | 71.5 | 53.1 |
| At Week 16 | 71.5 | 50.0 |
| At Week 20 | 66.2 | 56.3 |
| At Week 24 | 66.2 | 53.1 |
The 6MWT is a well-established performance outcome (PerfO) measure that is widely used to evaluate physical activity in terms of distance walked in patients with a variety of conditions. The test measures the distance an individual can walk on a hard, flat surface in 6 minutes.
| Meters | Mitapivat | Placebo |
|---|---|---|
| Double-Blind Period: Change From Baseline in the 6-minute Walk Test (6MWT) Distance at Week 24 | 30.48 ± 5.651 | 7.11 ± 7.346 |
Iron metabolism was assessed based on serum ferritin levels.
| Microgram/Liter (mcg/L) | Mitapivat | Placebo |
|---|---|---|
| Double-Blind Period: Change From Baseline in Serum Ferritin at Week 24 | -34.75 ± 32.710 | -32.48 ± 43.090 |
Iron metabolism was assessed based on TSAT levels. Transferrin saturation is reported by dividing value of serum iron by total iron binding capacity.
| Ratio | Mitapivat | Placebo |
|---|---|---|
| Double-Blind Period: Change From Baseline in Transferrin Saturation (TSAT) at Week 24 | -0.029 ± 0.0212 | -0.047 ± 0.0262 |
AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of AEs was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.
| Participants | Mitapivat | Placebo |
|---|---|---|
| Participants with TEAEs | 107 | 50 |
| Participants with Serious TEAEs | 8 | 0 |
| Participants with TEAEs related to study drug | 56 | 13 |
| Participants with any TEAE of Grade ≥ 3 | 18 | 2 |
| nanograms per milliliter (ng/mL) | Mitapivat |
|---|---|
| Pre-dose at Week 12 | 59.23 ± 51.081 |
| Pre-dose at Week 20 | 84.70 ± 138.852 |
| 30 Minutes Post-dose at Week 20 | 1209.00 ± 931.211 |
| 1 Hour Post-dose at Week 20 | 1386.35 ± 712.996 |
| 3 Hour Post-dose at Week 20 | 740.26 ± 357.660 |
| 5 Hour Post-dose at Week 20 | 359.42 ± 269.758 |
| 7 Hour Post-dose at Week 20 | 206.82 ± 185.657 |
Area under the concentration-time curve from time zero to Tlast on dosing day, calculated using the linear-log trapezoidal rule.
| Hours*nanogram per milliliter (h*ng/mL) | Mitapivat |
|---|---|
| Double-Blind Period: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mitapivat | 4262.57 ± 31.4 |
| hours | Mitapivat |
|---|---|
| Double-Blind Period: Time of Last Quantifiable Concentration (Tlast) of Mitapivat | 6.825 (6.50 to 7.42) |
| ng/mL | Mitapivat |
|---|---|
| Double-Blind Period: Maximum Observed Plasma Concentration (Cmax) of Mitapivat | 1565.69 ± 42.4 |
| Hours | Mitapivat |
|---|---|
| Double-Blind Period: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mitapivat | 1.000 (0.20 to 5.00) |
| ng/mL | Mitapivat |
|---|---|
| Double-Blind Period: Last Quantifiable Plasma Concentration (Clast) of Mitapivat | 166.93 ± 80.1 |
| microgram/milliliter (mcg/mL) | Mitapivat | Placebo |
|---|---|---|
| At Pre-dose at Day 1 | 180.87 ± 29.577 | 184.91 ± 31.299 |
| Pre-dose at Week 12 | 242.07 ± 45.782 | 176.81 ± 33.657 |
| Pre-dose at Week 20 | 235.79 ± 46.099 | 168.10 ± 29.962 |
| 30 Minutes Post-dose at Week 20 | 417.87 ± 102.853 | 457.78 ± 89.932 |
| 1 Hour Post-dose at Week 20 | 417.83 ± 105.752 | 457.71 ± 104.431 |
| 3 Hour Post-dose at Week 20 | 409.73 ± 96.379 | 454.39 ± 107.966 |
| 5 Hour Post-dose at Week 20 | 412.72 ± 94.150 | 464.24 ± 97.007 |
| 7 Hour Post-dose at Week 20 | 404.43 ± 97.586 | 471.10 ± 113.165 |
| mcg/mL | Mitapivat | Placebo |
|---|---|---|
| Pre-dose at Day 1 | 526.40 ± 125.196 | 506.14 ± 108.033 |
| Pre-dose at Week 12 | 434.90 ± 97.901 | 497.68 ± 112.055 |
| Pre-dose at Week 20 | 426.30 ± 107.173 | 468.22 ± 99.783 |
| 30 Minutes Post-dose at Week 20 | 417.87 ± 102.853 | 457.78 ± 89.932 |
| 1 Hour Post-dose at Week 20 | 417.83 ± 105.752 | 457.71 ± 104.431 |
| 3 Hour Post-dose at Week 20 | 409.73 ± 96.379 | 454.39 ± 107.966 |
| 5 Hour Post-dose at Week 20 | 412.72 ± 94.150 | 464.24 ± 97.007 |
| 7 Hour Post-dose at Week 20 | 404.43 ± 97.586 | 471.10 ± 113.165 |
AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of abnormalities was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.
Results for this outcome have not been posted.
Collected over Double-blind period: From the time of signing informed consent to Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mitapivat | 0/130 (0%) | 8/129 (6.2%) | 80/129 (62%) |
| Placebo | 0/64 (0%) | 0/63 (0%) | 33/63 (52.4%) |
| Event | Mitapivat | Placebo |
|---|---|---|
| Lower respiratory tract infectionInfections and infestations | 1/129 | 0/63 |
| PneumoniaInfections and infestations | 1/129 | 0/63 |
| Upper respiratory tract infectionInfections and infestations | 1/129 | 0/63 |
| Craniofacial fractureInjury, poisoning and procedural complications | 1/129 | 0/63 |
| Ulna fractureInjury, poisoning and procedural complications | 1/129 | 0/63 |
| AnaemiaBlood and lymphatic system disorders | 1/129 | 0/63 |
| Angina pectorisCardiac disorders | 1/129 | 0/63 |
| Abdominal painGastrointestinal disorders | 1/129 | 0/63 |
| Superficial vein thrombosisVascular disorders | 1/129 | 0/63 |
| Event | Mitapivat | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 29/129 | 6/63 |
| Initial insomniaPsychiatric disorders | 18/129 | 3/63 |
| NauseaGastrointestinal disorders | 15/129 | 5/63 |
| Upper respiratory tract infectionInfections and infestations | 13/129 | 4/63 |
| InfluenzaInfections and infestations | 5/129 | 6/63 |
| DiarrhoeaGastrointestinal disorders | 11/129 | 6/63 |
| PyrexiaGeneral disorders | 4/129 | 6/63 |
| FatigueGeneral disorders | 12/129 | 4/63 |
| COVID-19Infections and infestations | 8/129 | 5/63 |
| Back painMusculoskeletal and connective tissue disorders | 3/129 | 5/63 |
Full Analysis Set (FAS) included all participants who were randomized.
| Age, Continuous(years) | Mitapivat | Placebo | Total |
|---|---|---|---|
| Mean | 42.4 ± 13.03 | 38.9 ± 12.99 | 41.2 ± 13.09 |
| Sex: Female, Male(Participants) | Mitapivat | Placebo | Total |
|---|---|---|---|
| Female | 84 | 39 | 123 |
| Male | 46 | 25 | 71 |
| Ethnicity (NIH/OMB)(Participants) | Mitapivat | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 6 | 17 |
| Not Hispanic or Latino | 118 | 58 | 176 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Mitapivat | Placebo | Total |
|---|---|---|---|
| White | 73 | 36 | 109 |
| Asian | 52 | 24 | 76 |
| Black or African American | 1 | 1 | 2 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Multiracial | 1 | 0 | 1 |
| Unknown | 2 | 2 | 4 |
| Not reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2021 to primary completion in Nov 2023, 22 months.
Results were first posted in Jan 2025, 1 year 2 months after primary completion.
Of 18 phase 3 interventional studies under beta-Thalassemia, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's 22 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mitapivat